Long-term outcomes of infliximab treatment and predictors of response in 195 patients with ulcerative colitis: a hospital-based cohort study from Korea

Hyungil Seo, Kiju Chang, Sun Ho Lee, Eun Mi Song, Gwang Un Kim, Myeongsook Seo, Ho Su Lee, Sung Wook Hwang, Dong Hoon Yang, Kyung Jo Kim, Byong Duk Ye, Jeong Sik Byeon, Seung Jae Myung, Suk Kyun Yang, Sang Hyoung Park

Research output: Contribution to journalArticlepeer-review

6 Scopus citations

Abstract

Background: Large-scale studies regarding the long-term efficacy of infliximab (IFX) treatment in non-Caucasian patients with ulcerative colitis (UC) are lacking. Study: We analyzed the long-term outcomes of IFX in 195 Korean UC patients who received scheduled IFX treatments at Asan Medical Center. IFX failure was defined as IFX discontinuation due to colectomy or non-response to IFX, and additionally UC-related hospitalization or a need for rescue corticosteroids during the course of IFX. Results: Between December 2006 and October 2016, a total of 3101 infusions of IFX were administered to 195 patients over a median period of 21 months. At the end of the follow-up, 86 patients (44.1%) were still receiving IFX without failure. IFX was stopped in 73 (37.4%) patients due to colectomy (23 patients, 11.8%), non-response to IFX (35 patients, 17.9%) or other reasons such as adverse events or patients’ preferences (15 patients, 7.7%). An additional 36 (18.5%) patients experienced IFX failure during follow-up due to a need for rescue corticosteroids (13 patients, 6.7%), UC-related hospitalization (8 patients, 4.1%), or both (15 patients, 7.7%). The survival free of IFX failure was 58.1% at 1 year, 50.7% at 3 years and 44.8% at 5 years. In a multivariate regression analysis, cytomegalovirus colitis within 3 months before IFX initiation was a predictor of IFX failure (hazard ratio 1.57; 95% confidence interval 1.04–2.37; p =.032). Conclusions: The long-term efficacy of IFX in a large, real-life cohort of Korean UC patients appears to be comparable to that in previously published Western studies.

Original languageEnglish
Pages (from-to)857-863
Number of pages7
JournalScandinavian Journal of Gastroenterology
Volume52
Issue number8
DOIs
StatePublished - 3 Aug 2017

Keywords

  • infliximab
  • Korea
  • outcome
  • Ulcerative colitis

Fingerprint

Dive into the research topics of 'Long-term outcomes of infliximab treatment and predictors of response in 195 patients with ulcerative colitis: a hospital-based cohort study from Korea'. Together they form a unique fingerprint.

Cite this